Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
(Paris:VLA),(Paris:VLAP), Saint-Herblain (France), January 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ(R), which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously […]